
Sodium-glucose co‐transporter 2 inhibitors (SGLT2i) may induce an early post‐initiation eGFR decrease which does not impact the SGLT2i benefits. The occurrence, characteristics, determinants, and clinical significance of an initial eGFR change among patients with heart failure with reduced ejection fraction (HFrEF) require further study. To describe eGFR change from randomisation to week 4 (as % of change relative to randomisation) and assess its impact in EMPEROR‐Reduced. A mild eGFR decrease may be expected after the initiation of empagliflozin, and it is not associated with untoward HF, mortality or kidney safety events. Clinicians should not be concerned with early eGFR changes post‐initiation of empagliflozin.
Like
Save
Share